NCT Number: NCT05588609 Phase: Phase 2 Trial Summary: This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following di – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Merus N.V. Acronym:
Clinical Trials
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
December 11th, 2023 | Clinical TrialsPhase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
December 11th, 2023 | Clinical TrialsNCT Number: NCT05585034 Phase: Phase 1 Trial Summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Xencor, Inc. Acronym:
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
December 11th, 2023 | Clinical TrialsNCT Number: NCT05597878 Phase: Phase 2|Phase 3 Trial Summary: The objective of this study is to conduct a randomized clinical trial to evaluate an opioid versus an opioid-free pathway of perioperative use of ketamine, ketorolac, and IV acetam – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Wake Forest University Health Sciences Acronym:
Wrist Cooling for Hot Flashes Clinical Trial
December 11th, 2023 | Clinical TrialsNCT Number: NCT05595213 Phase: NA Trial Summary: This pilot randomized double blind controlled crossover study aims to determine the impact of two wrist cooling devices on symptom control of hot flashes in adult men with prostate – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Boston University Acronym:
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
December 11th, 2023 | Clinical TrialsNCT Number: NCT05477823 Phase: Early Phase 1 Trial Summary: The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will und – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Wisconsin, Madison Acronym:
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors
December 11th, 2023 | Clinical TrialsNCT Number: NCT05488548 Phase: Phase 1 Trial Summary: A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Epigenetix, Inc. Acronym:
Improving Germline Testing in At-Risk Patients With Prostate Cancer
December 11th, 2023 | Clinical TrialsNCT Number: NCT05470036 Phase: Not Applicable Trial Summary: A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational sessi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of California, San Diego Acronym: IMPRINT
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
December 11th, 2023 | Clinical TrialsNCT Number: NCT05519449 Phase: Phase 1 Trial Summary: This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Janux Therapeutics Acronym:
MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Intermediate Grade Prostate Cancer
December 11th, 2023 | Clinical TrialsNCT Number: NCT05438563 Phase: Not Applicable Trial Summary: This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in treating patients with in – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Mayo Clinic Acronym:
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
December 11th, 2023 | Clinical TrialsNCT Number: NCT05415098 Phase: Phase 1 Trial Summary: This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG- – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Ascentage Pharma Group Inc. Acronym: